



This report is prepared for the Warsaw Stock Exchange SA within the framework of the Analytical Coverage Support Program 3.0.

375/2023/AR

June 16, 2023

Company	LT fundamental recommendation	12M EFV (PLN)	ST market-relative bias	Analyst
BioMaxima	Not rated	36.40	Not rated	Sylvia Jaśkiewicz, CFA Mikołaj Stępień

Event: New production facility finished

Yesterday the Company's management informed about a reception of the occupancy permit for a newly constructed production plant. Moreover, the warehouse and office area in the building BioMaxima bought earlier was finally adapted and the Company started to set up the production and lab equipment.

The last stage of the pending investments will be the capacity expansion in another building owned by Biomaxima which is scheduled for 3Q23. Due to the above mentioned investments the Company's infrastructure will increase to 6,000 sq m.

Expected impact: *Neutral*

The report is not a recommendation within the meaning of Commission Delegated Regulation (EU) 2016/958 of 9 March 2016 supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest.